Angoulvant Denis, Fazel Shafie, Li Ren-Ke
Toronto General Research Institute, Toronto General Hospital, Toronto, Canada.
Mol Cell Biochem. 2004 Sep;264(1-2):133-42. doi: 10.1023/b:mcbi.0000044382.02403.9c.
Myocardial ischemia triggers a limited angiogenic response, part of the remodeling process that is insufficient to avoid further functional impairment. Several strategies have been evaluated to regenerate myocardial vascularization after ischemic injury such as transmyocardial laser revascularization and gene therapy. Attention has recently been focused on the potential of cell therapy to induce angiogenesis. Enhancing myocardial neovascularization is a major goal of myocardial cell transplantation because it would provide patients, who cannot undergo conventional revascularization, with an alternative therapy. Additionally, neovascularization would provide the implanted cells with adequate microenvironment to enhance survival and function. This short review gives an overview of the effect of various cell transplantation strategies on myocardial neovascularization. It suggests that in order to optimize myocardial neovascularization induced by cell therapy, future experiments should focus on the contribution of exogenous and endogenous stem cells to new vessels formation, and on the identification of the molecular pathways involved in the process.
心肌缺血引发有限的血管生成反应,这是重塑过程的一部分,不足以避免进一步的功能损害。已经评估了多种策略来在缺血性损伤后再生心肌血管化,如经心肌激光血运重建术和基因治疗。最近,注意力集中在细胞治疗诱导血管生成的潜力上。增强心肌新生血管形成是心肌细胞移植的主要目标,因为这将为无法接受传统血运重建的患者提供一种替代疗法。此外,新生血管形成将为植入细胞提供适当的微环境以提高其存活率和功能。这篇简短的综述概述了各种细胞移植策略对心肌新生血管形成的影响。它表明,为了优化细胞治疗诱导的心肌新生血管形成,未来的实验应关注外源性和内源性干细胞对新血管形成的贡献,以及参与该过程的分子途径的识别。